Cite
HARVARD Citation
Thomas, A. et al. (2020). Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. European journal of cancer. pp. 131-141. [Online].